🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT04779008
Recruiting Not applicable

Long-term Remote Ischemic Preconditioning Improves Myocardial Perfusion and Prognosis of Patients After CABG

NCT04779008 · tracked via the Priya Life Science China tracker
Sponsor
Henan Institute of Cardiovascular Epidemiology
Phase
Not applicable
Started
2021-03-10
Last updated
2025-09-18

Condition(s) studied

Coronary Disease

Investigational drug(s) / intervention(s)

remote ischemic preconditioning (RIPC)

remote ischemic preconditioning (RIPC): Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff inflated to 200 mmHg.

Study summary

Remote Ischemic preconditioning (RIPC) has been reported to improve myocardial microcirculation, promote collateral circulation recruitment, and improve myocardial perfusion in patients.Two large randomized controlled trials demonstrated a perioperative cardioprotective effect of RIPC (reduced troponin levels), but did not find that a single preoperative RIPC improved long-term outcomes of coronary artery bypass grafting(CABG).The effect of a single RIPC before CABG may be too short. This study aims to investigate whether long-term RIPC improved myocardial perfusion in patients 3 months and 6 months after CABG surgery , and to detect changes in blood vascular endothelial growth factor, Nitrc Oxide, adenosine,and Endothelin-1, and to observe MACCE event rates at 12 months.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Three coronary artery lesions, CABG surgery was planned Exclusion Criteria: * The patients could not tolerate ripc; * peripheral vascular disease affecting upper limbs * Acute myocardial infarction complicated with cardiogenic shock,in recent 30 days, * Emergency cases * Severe structural heart disease and severe arrhythmia ; * The uncontrolled systolic blood pressure and diastolic blood pressure of severe hypertension were 180 mmHg and 120 mmHg respectively; * Severe liver, renal and pulmonary disease * Mental disorder can't cooperate; * Inability to give informed consent; * Patients on glibenclamide or nicorandil, as these medications may interfere with RIC * pregnant;

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Fuwai central China cardiovascular Hospital Zhengzhou Henan Recruiting

More Henan Institute of Cardiovascular Epidemiology trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04779008 on ClinicalTrials.gov ↗ ← All trials in China